You are here: Industry Insights > Market News > ValenzaBio, ProBioGen Enter Cell Line Pact

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

SG-DJ10 Capsule and Tablet Sample Checkweigher

NADP+

NMN

Ceritinib (LDK378) CAS:1032900-25-6

SG-JN10 0.1mg Tablet Capsule Check Weigher

β-Nicotinamide Adenine Dinucleotide (NAD+)

ValenzaBio, ProBioGen Enter Cell Line Pact

contractpharmaJuly 29, 2021

Tag: ValenzaBio , ProBioGen , VB119

Favorites

ProBioGen and ValenzaBio have initiated a cell line development project involving the application of ProBioGen's GlymaxX technology.

ProBioGen will generate a new CHO-based expression system for ValenzaBio's VB119, a clinical-stage antibody. In addition to the CHO.RiGHT cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology. GlymaxX enables a fine tuning of the fucose content of the antibody towards the originator molecule's fucose content. The GlymaxX technology offers flexibility in terms of fucosylation adjustment and enables its application for innovative molecules as well as for biosimilar projects.

Previous:ImmunoGenesis Opens Research Lab, Adds Key Roles

Next:Cerba Research Wins NIH Contract for Central Lab Services

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

ValenzaBio, ProBioGen Enter Cell Line Pact | Pharmasources.com

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

MetP Pharma AG today announced tirzepatide in a BrainDos™ formulation reduced pro-inflammatory cytokine Il-6 by more than 80% and 2-fold stronger than with aqueous tirzepatide solution.

ValenzaBio, ProBioGen Enter Cell Line Pact

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may like
More>>

ValenzaBio, ProBioGen Enter Cell Line Pact

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may likeMore>>

You may like
More>>